AskRx Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 8.8/10
Best for: coverage in all 50 states, which most of the register will not confirm
What AskRx does best is charge less than most of the register.
Covered by the monthly price
Medication
Not stated
Clinician visits
Not stated
Shipping
Not stated
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
The subscription buys a physician, not a drug: $99-149/mo, with medication invoiced separately. AskRx never dispenses, compounds or sells anything; it routes the script to a manufacturer pharmacy, NovoCare or LillyDirect, whichever the patient picks. Its board-certified physicians write nothing compounded, only FDA-approved brand-name GLP-1s: Zepbound (tirzepatide), plus the Wegovy pen and pill (semaglutide). LegitScript approval and HIPAA compliance are claimed across all 50 states, and the subscription may qualify for HSA/FSA.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to AskRx
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
AskRx at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Wegovy pen & pill, Zepbound
- Starting price
- $199/mo
- Availability
- All 50 states
- FDA status
- No FDA warning letter on record
How AskRx scores
Six columns, each one computed from something AskRx has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
10.0/10$349/month is 73% below the register median of $1299 for brand semaglutide.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, including the FDA-approved product. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
7.5/10does not name a dispensing pharmacy; shows a price before asking for health information; publishes its state list. Our verification confidence is medium.
Accessibility10%
10.0/10Publishes coverage in 50 of 50 states.
Support10%
5.0/10States too little about what the monthly cost covers to score the bundle. Held at the midpoint rather than assumed.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on AskRx
Last checked June 2026- Re-read the price on file across 4 dose or plan tiers
- Checked state coverage: all 50
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
What signing up with AskRx involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1AskRx publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3AskRx does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- Cheapest standing monthly prices on record: semaglutide $199, tirzepatide $299. Membership fees, first-month rates and insured copays are excluded from those figures.
- Coverage is published for all 50 states.
GLP-1 medications AskRx offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
Check the price yourself before you pay
Every figure here was read off AskRx's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Semaglutide at $199 a month, 85% below the $1299 median for the same drug and form across this register
- Tirzepatide at $299 a month, 76% below the $1249 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- Coverage is published for all 50 states
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
What AskRx charges
The standing price at AskRx is $199/month. That sits above the middle of the market, which puts the burden on whatever else is in the package.
- Brand-name semaglutide — $199/month
- Brand-name semaglutide — $349/month
- Brand-name tirzepatide — $299/month
- Brand-name tirzepatide — $449/month
The median standing price across the GLP-1 providers we track is about $169/month, so this is a premium, and a premium has to buy something. Check what is bundled before accepting it.
Found dispenses semaglutide and tirzepatide from $149/month, which makes it the honest comparison to run before committing here.
What AskRx dispenses
AskRx prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data. These are FDA-approved brand-name products rather than compounded preparations, which is the more expensive route and the one where what is in the vial has been reviewed.
What we could verify
On the record: it treats patients in all 50 states. We searched the federal warning-letter record for this operator and came back with nothing. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You are optimizing for the twelve-month total rather than the first bill — a flat-rate seller such as CoreAge Rx will usually win that arithmetic.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- you need access regardless of where you live
Our read
AskRx costs more than the middle of this market. If the extras it charges for are ones you would actually use, that is a defensible trade. If not, the same molecule is available for less. Breeze Meds is the nearest comparison we track, and worth reading alongside this.
The Bottom Line
What AskRx does best is charge less than most of the register.
Before you pay AskRx
Starting at $199/month. Check today's price, then book the free consultation.
Where AskRx is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this AskRx review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See AskRx's current pricing
Plans start at $199/month. The free consultation is where you learn whether you qualify, and what it costs today.